세계의 알코올 사용 장애(AUD) 시장 : 지역 및 국가별 분석과 예측(2025-2035년)

Market Lifecycle Stage

The global alcohol use disorder market is currently in the growth stage of its lifecycle. This phase is characterized by a rising demand for innovative treatments and increased recognition of alcohol use disorder as a significant public health issue. The market is benefiting from advancements in personalized medicine, where treatments are tailored to individuals based on genetic profiles, as well as the development of new pharmacotherapies that offer more effective and targeted solutions. Additionally, the market is being driven by the growing integration of behavioral therapies with pharmacological treatments, creating more comprehensive and effective care models. Another key factor in the market's growth is the increasing adoption of digital health technologies, including telemedicine and online support platforms, which make alcohol use disorder treatments more accessible, especially in underserved regions. This is coupled with a global push for better addiction treatment infrastructure, expanding both the reach and availability of care. Despite these opportunities, challenges such as high treatment costs and social stigmas related to addiction still persist, especially in developing markets, potentially limiting the broader adoption of treatment solutions. However, as public health initiatives continue to promote awareness and access, the market is expected to grow further and move toward a more mature stage in the coming years.

Impact

• Increasing demand for alcohol use disorder therapies is anticipated to support the growth of the global alcohol use disorder market during the forecast period 2025-2035.
• The global alcohol use disorder market is expected to grow at a significant rate due to developments in targeted therapies, rising awareness and diagnosis, and a growing clinical pipeline, alongside advancements in healthcare infrastructure and access to specialized treatments.

Recent Developments

• Research Activities: In May 2025, Adial Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office had issued U.S. Patent No. 12,274,692, covering an innovative method for treating alcohol-related and opioid-related disorders using AD04 in genetically defined patient populations.

Demand - Drivers and Limitations

Drivers:

• Increasing Prevalence of Alcohol Use Disorder
• Improved Diagnostic Criteria and Screening Tools

Limitations:

• Limited Treatment Options for Specific Populations

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Innovations in the global alcohol use disorder market are centered on advancing treatment options to enhance patient care. Key players in the market, such as Adial Pharmaceutical, Inc., have been involved in the development of therapies for alcohol use disorder.

Competitive Strategy: Enterprises led by market leaders continually update their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product pipeline and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolios, and market penetration.

Some of the prominent names established in this market are:

• Clearmind Medicine Inc.
• Purdue Pharma L.P.
• Psyence Biomedical
• Eli Lilly and Company
• Tempero Bio, Inc.
• Nxera Pharma Co., Ltd.
• Novo Nordisk A/S
• Adial Pharmaceuticals
• Alkermes
• Lundbeck

Table of Contents

Executive Summary

Scope of Study

1. Global Alcohol Use Disorder Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Market Trends
• 1.3 Epidemiological Analysis of Alcohol Use Disorder
  • 1.3.1 By Region
• 1.4 Clinical Trials
  • 1.4.1 By Phase
  • 1.4.2 By Sponsor Type
• 1.5 Regulatory Landscape / Compliance
  • 1.5.1 Legal Requirement and Framework in the U.S.
  • 1.5.2 Legal Requirement and Framework in the E.U.
  • 1.5.3 Legal Requirement and Framework in Asia-Pacific
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Alcohol Use Disorder Market, By Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Size and Forecast
    • 2.1.2.1 North America Alcohol Use Disorder Market (by Country)
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Size and Forecast
    • 2.2.2.1 Europe Alcohol Use Disorder Market (by Country)
      • 2.2.2.1.1 U.K.
      • 2.2.2.1.2 Germany
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Size and Forecast
    • 2.3.2.1 Asia-Pacific Alcohol Use Disorder Market (by Country)
      • 2.3.2.1.1 Japan

3. Global Alcohol Use Disorder Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 Clearmind Medicine Inc.
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Analyst View
  • 3.2.2 Purdue Pharma L.P.
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers/End Users
    • 3.2.2.4 Analyst View
  • 3.2.3 Psyence Biomedical
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers/End Users
    • 3.2.3.4 Analyst View
  • 3.2.4 Eli Lilly and Company
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers/End Users
    • 3.2.4.4 Analyst View
  • 3.2.5 Tempero Bio, Inc.
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Product Portfolio
    • 3.2.5.3 Target Customers/End Users
    • 3.2.5.4 Analyst View
  • 3.2.6 Nxera Pharma Co., Ltd.
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Product Portfolio
    • 3.2.6.3 Target Customers/End Users
    • 3.2.6.4 Analyst View
  • 3.2.7 Novo Nordisk A/S
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Product Portfolio
    • 3.2.7.3 Target Customers/End Users
    • 3.2.7.4 Analyst View
  • 3.2.8 Adial Pharmaceuticals
    • 3.2.8.1 Company Overview
    • 3.2.8.2 Product Portfolio
    • 3.2.8.3 Target Customers/End Users
    • 3.2.8.4 Analyst View
  • 3.2.9 Alkermes
    • 3.2.9.1 Company Overview
    • 3.2.9.2 Product Portfolio
    • 3.2.9.3 Target Customers/End Users
    • 3.2.9.4 Analyst View
  • 3.2.10 Lundbeck
    • 3.2.10.1 Company Overview
    • 3.2.10.2 Product Portfolio
    • 3.2.10.3 Target Customers/End Users
    • 3.2.10.4 Analyst View

4. Research Methodology